



Company Announcement

Nykode Therapeutics ASA - Notice of Extraordinary General Meeting

Oslo, Norway, April 2, 2025 – The Board of Directors of Nykode Therapeutics ASA (OSE: NYKD) hereby calls for an Extraordinary General Meeting (EGM) to be held at meeting room FORUM - Building H, Floor 0 in Gaustadalléen 21, Oslo, Norway at 14:00 CEST on April 23, 2025.

The purpose of the meeting is to elect a new Board of Directors.

The notice of the EGM is attached. All documents regarding the EGM will also be made available at the Company's website: <https://nykode.com/investors/shareholder-meetings/>

For further information, please see the Company's website or contact the Company at IR@nykode.com.

This information is subject to the disclosure requirements pursuant to sections 5-12 of the Norwegian Securities Trading Act.

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is currently being further developed in head and neck cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in 2 trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at <http://www.nykode.com>.



Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

Michael Engsig, Chief Executive Officer
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway